FGF23 and chronic kidney disease: Clinical studies have shown that R. roxburghii can resist renal interstitial fibrosis by regulating the expression of “fibroblast growth factor 23 (FGF23)—Klotho protein axis” in patients, which has a good role in delaying the progress of chronic kidney disease, and has a better efficacy and safety for patients with spleen—kidney—deficiency CKD stage 3 [126].